Omeprazole is one of the most commonly prescribed medications in the UK, used to treat conditions such as gastro-oesophageal reflux disease (GORD) and peptic ulcers. With millions of people taking proton pump inhibitors (PPIs) long-term, questions naturally arise about potential side effects, including concerns about liver health. Fatty liver disease affects approximately one in three UK adults, often linked to obesity, diabetes, and metabolic syndrome. This article examines whether omeprazole causes fatty liver, reviews the current evidence, and explains when to seek medical advice about liver concerns whilst taking this medication.
Summary: There is no established direct causal link between omeprazole use and the development of fatty liver disease.
- Omeprazole is a proton pump inhibitor that reduces stomach acid by blocking the proton pump in gastric parietal cells.
- Fatty liver disease is not listed as a recognised adverse effect in the MHRA or EMA regulatory documentation for omeprazole.
- Rare liver-related side effects of omeprazole include hepatocellular injury and cholestatic hepatitis, which differ from fatty liver accumulation.
- Fatty liver disease is primarily associated with obesity, type 2 diabetes, dyslipidaemia, and metabolic syndrome rather than medication use.
- Patients with severe hepatic impairment require caution and possible dose adjustment when taking omeprazole.
- Long-term PPI users should have regular medication reviews to monitor for potential adverse effects and assess continued clinical need.
Table of Contents
Am I eligible for weight loss injections?
Find out whether you might be eligible!
Answer a few quick questions to see whether you may be suitable for prescription weight loss injections (like Wegovy® or Mounjaro®).
- No commitment — just a quick suitability check
- Takes about 1 minute to complete
What Is Omeprazole and How Does It Work?
Omeprazole is a proton pump inhibitor (PPI) widely prescribed in the UK for conditions involving excessive stomach acid production. It is commonly used to treat gastro-oesophageal reflux disease (GORD, also known as GERD), peptic ulcers, and as part of Helicobacter pylori eradication therapy. The medication is available both on prescription and over the counter from pharmacies for short-term use (up to four weeks) in lower doses. If symptoms persist or recur, you should seek advice from your GP.
Mechanism of Action
Omeprazole works by irreversibly blocking the hydrogen-potassium adenosine triphosphatase enzyme system (the proton pump) in the gastric parietal cells of the stomach lining. This action significantly reduces the production of gastric acid, providing relief from acid-related symptoms and allowing damaged oesophageal or gastric tissue to heal. The drug is absorbed in the small intestine and activated in the acidic environment of the parietal cells, where it forms covalent bonds with the proton pump.
The effects of omeprazole are long-lasting because new proton pumps must be synthesised before acid secretion can resume, which typically takes several days. This explains why the medication is usually taken once daily, preferably in the morning before food. According to NICE guidance (CG184 and Clinical Knowledge Summaries on dyspepsia and GORD), omeprazole should be prescribed at the lowest effective dose for the shortest duration necessary to control symptoms, with regular review to ensure continued clinical need.
Common Uses and Duration
Typical treatment courses range from two to eight weeks for most conditions, though some patients with severe GORD or Barrett's oesophagus may require long-term maintenance therapy. The MHRA recommends regular review of patients on prolonged PPI therapy to monitor for potential adverse effects associated with extended use. In patients with severe hepatic impairment, caution is advised and dose adjustment may be necessary, as stated in the omeprazole Summary of Product Characteristics (SmPC).
Understanding Fatty Liver: Causes and Risk Factors
Fatty liver disease, medically termed hepatic steatosis, occurs when excess fat accumulates in liver cells. In the UK, this condition has become increasingly prevalent, affecting an estimated one in three adults to some degree. There are two main categories: alcoholic fatty liver disease (AFLD) and non-alcoholic fatty liver disease (NAFLD), with the latter being far more common.
Non-Alcoholic Fatty Liver Disease (NAFLD)
NAFLD develops in people who drink little or no alcohol and is strongly associated with metabolic syndrome. The primary risk factors include:
-
Obesity and overweight – particularly central adiposity
-
Type 2 diabetes mellitus – up to 70% of people with type 2 diabetes have NAFLD
-
Dyslipidaemia – elevated triglycerides and low HDL cholesterol
-
Insulin resistance – a key pathophysiological mechanism
-
Hypertension – often coexists with other metabolic risk factors
The condition exists on a spectrum, ranging from simple steatosis (fat accumulation alone) to non-alcoholic steatohepatitis (NASH), which involves inflammation and liver cell damage. NASH can progress to fibrosis, cirrhosis, and hepatocellular carcinoma in some individuals.
Other Contributing Factors
Additional risk factors include certain medications (such as corticosteroids, tamoxifen, and some antiretroviral drugs), rapid weight loss, total parenteral nutrition, and genetic predisposition. Age over 50 and South Asian ethnicity also increase risk. Most people with fatty liver disease experience no symptoms in the early stages, and the condition is often detected incidentally through imaging or abnormal liver function tests performed for other reasons. It is important to note that liver blood tests can be normal in people with NAFLD.
Management and Lifestyle Advice
The NHS and NICE (NG49) recommend lifestyle modification as the cornerstone of NAFLD management. This includes gradual weight loss of 5–10% of body weight if overweight or obese, increased physical activity (at least 150 minutes of moderate-intensity aerobic activity per week), a Mediterranean-style dietary pattern, and keeping alcohol consumption within UK low-risk guidelines (no more than 14 units per week, spread over three or more days).
When to Seek Medical Advice About Liver Concerns
Recognising when liver-related symptoms require medical attention is crucial for early intervention and preventing serious complications. Whilst fatty liver disease often remains asymptomatic in its early stages, certain signs and symptoms warrant prompt evaluation by your GP or healthcare provider.
Warning Signs Requiring Medical Assessment
You should contact your GP if you experience:
-
Persistent fatigue or weakness that interferes with daily activities
-
Unexplained weight loss without dietary changes
-
Abdominal discomfort or pain in the upper right quadrant
-
Jaundice – yellowing of the skin or whites of the eyes
-
Dark urine or pale-coloured stools
-
Persistent nausea or loss of appetite
-
Easy bruising or bleeding that occurs without obvious cause
-
Swelling in the legs or abdomen (oedema or ascites)
Urgent Medical Attention
Seek immediate medical help (call 999 or attend A&E) if you develop severe abdominal pain, confusion, vomiting blood, or black tarry stools, as these may indicate serious liver complications requiring emergency treatment.
Assessment and Risk Stratification for NAFLD
If you have risk factors for liver disease—such as diabetes, obesity, high cholesterol, or long-term medication use—discuss liver health with your GP. According to NICE guidance (NG49), if NAFLD is suspected or incidentally identified (for example, on imaging or through abnormal liver blood tests in someone with metabolic risk factors), your GP should use a non-invasive scoring system such as the FIB-4 score or NAFLD fibrosis score to assess the likelihood of advanced liver fibrosis. If these scores suggest possible advanced fibrosis, a second-line test such as the Enhanced Liver Fibrosis (ELF) blood test may be arranged. Patients with suspected advanced fibrosis or cirrhosis should be referred to a hepatology specialist for further assessment.
Liver function tests typically include measurements of alanine aminotransferase (ALT), alkaline phosphatase (ALP), bilirubin, and albumin, with gamma-glutamyl transferase (GGT) sometimes included. Aspartate aminotransferase (AST) may not be routinely measured in all UK laboratories. It is important to understand that normal liver blood tests do not exclude NAFLD, as many people with fatty liver have normal results.
Medication Review
If you're taking omeprazole or other medications long-term, periodic review appointments allow your healthcare provider to assess ongoing need, monitor for adverse effects, and check liver function if clinically indicated. Never stop prescribed medications without consulting your doctor, even if you're concerned about potential side effects.
Can Omeprazole Cause Fatty Liver Disease?
The relationship between omeprazole and fatty liver disease is not straightforward, and there is no established direct causal link between omeprazole use and the development of fatty liver disease. However, understanding the nuances of this topic requires examining the available evidence and considering the broader context of liver health.
Current Evidence and Regulatory Position
The MHRA Summary of Product Characteristics (SmPC) and the European Medicines Agency (EMA) European Public Assessment Report (EPAR) for omeprazole do not list fatty liver disease or hepatic steatosis as a recognised adverse effect. Omeprazole is primarily metabolised by the liver through the cytochrome P450 enzyme system, and whilst various hepatic adverse reactions have been documented, these are generally rare and differ from fatty liver disease.
Documented Liver-Related Adverse Effects
Omeprazole can, in rare cases, cause:
-
Hepatocellular injury – elevated liver enzymes (transaminases)
-
Cholestatic hepatitis – impaired bile flow
-
Hepatic encephalopathy – in patients with pre-existing severe liver disease
These reactions are uncommon, typically reversible upon discontinuation, and represent different pathological processes from fatty liver accumulation. Most patients taking omeprazole experience no liver-related problems whatsoever. In patients with severe hepatic impairment, caution is advised and dose adjustment may be necessary, as per the SmPC.
Observational Associations
Some observational studies have reported associations between long-term PPI use and NAFLD. However, the evidence is inconsistent, subject to confounding factors (such as shared metabolic risk factors), and does not establish causation. Theoretically, long-term PPI use might be associated with metabolic changes, including alterations in gut microbiota, nutrient absorption, and glucose metabolism, but current evidence does not support a direct mechanistic pathway from omeprazole to fatty liver development.
Clinical Perspective
If you have been diagnosed with fatty liver disease whilst taking omeprazole, it is far more likely that traditional risk factors—such as obesity, diabetes, or metabolic syndrome—are responsible rather than the medication itself. Your GP can assess your individual risk factors and determine whether any investigations or medication adjustments are appropriate. Do not discontinue omeprazole without medical advice, as untreated acid-related conditions can lead to serious complications including oesophageal strictures or Barrett's oesophagus.
If you have concerns about your liver health or medication, schedule a review appointment to discuss your specific circumstances with your healthcare provider. If you experience any suspected side effects from omeprazole or any other medicine, you can report them via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk or by searching for 'MHRA Yellow Card'.
Frequently Asked Questions
Can taking omeprazole long-term damage my liver?
Omeprazole does not typically cause liver damage in most people, and fatty liver disease is not a recognised side effect. Rare liver-related reactions such as elevated liver enzymes or cholestatic hepatitis can occur but are usually reversible when the medication is stopped, and your GP can monitor liver function if you're on long-term treatment.
What are the actual side effects of omeprazole on the liver?
Documented liver-related side effects of omeprazole are uncommon and include hepatocellular injury (elevated liver enzymes), cholestatic hepatitis (impaired bile flow), and hepatic encephalopathy in patients with pre-existing severe liver disease. These reactions differ from fatty liver disease and are typically reversible upon stopping the medication.
Should I stop taking omeprazole if I have fatty liver disease?
Do not stop omeprazole without consulting your GP, as untreated acid-related conditions can lead to serious complications such as oesophageal strictures or Barrett's oesophagus. If you have fatty liver disease whilst taking omeprazole, traditional risk factors like obesity, diabetes, or metabolic syndrome are far more likely to be responsible than the medication itself.
Is there a link between PPIs like omeprazole and non-alcoholic fatty liver disease?
Some observational studies have reported associations between long-term PPI use and NAFLD, but the evidence is inconsistent and does not establish causation. These studies are subject to confounding factors such as shared metabolic risk factors, and current evidence does not support a direct mechanistic pathway from omeprazole to fatty liver development.
How do I know if omeprazole is affecting my liver health?
Most people taking omeprazole experience no liver problems, but you should contact your GP if you develop jaundice (yellowing of skin or eyes), dark urine, pale stools, persistent fatigue, unexplained weight loss, or abdominal pain. Your doctor can arrange liver function tests and assess whether any symptoms are related to your medication or other underlying conditions.
What should I do if I'm worried about taking omeprazole with existing liver problems?
If you have pre-existing liver disease or concerns about liver health, discuss this with your GP before starting or continuing omeprazole. Patients with severe hepatic impairment may require dose adjustment, and your doctor can arrange regular monitoring and medication reviews to ensure the treatment remains safe and appropriate for your individual circumstances.
The health-related content published on this site is based on credible scientific sources and is periodically reviewed to ensure accuracy and relevance. Although we aim to reflect the most current medical knowledge, the material is meant for general education and awareness only.
The information on this site is not a substitute for professional medical advice. For any health concerns, please speak with a qualified medical professional. By using this information, you acknowledge responsibility for any decisions made and understand we are not liable for any consequences that may result.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Heading 6
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
- Item 1
- Item 2
- Item 3
Unordered list
- Item A
- Item B
- Item C
Bold text
Emphasis
Superscript
Subscript
